Hims & Hers Health

HIMS

Market cap $11.9B

Overview Fund Activity

52.63 USD

+2.28

4.53%

At close Updated Sep 18, 10:07 AM EDT

1 day

4.53%

5 days

3.14%

1 month

16.7%

3 months

-13.82%

6 months

67.13%

Year to date

108.85%

1 year

222.69%

5 years

370.33%

10 years

437.04%

About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Employees: 1,637

Consumer Staples Household & Personal Products

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

156% more first-time investments, than exits

New positions opened: 138 | Existing positions closed: 54

88% more capital invested

Capital invested by funds: $4.63B [Q1] → $8.72B (+$4.09B) [Q2]

33% more repeat investments, than reductions

Existing positions increased: 183 | Existing positions reduced: 138

18% more funds holding

Funds holding: 420 [Q1] → 496 (+76) [Q2]

7.98% more ownership

Funds ownership: 73.23% [Q1] → 81.21% (+7.98%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 9 [Q1] → 9 (+0) [Q2]

31% less call options, than puts

Call options by funds: $1.31B | Put options by funds: $1.91B

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$37

30% downside

Avg. target

$53

0% upside

High target

$68

29% upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Canaccord Genuity Maria Ripps	$68	Buy Maintained	12 Sep 2025
Truist Securities Jailendra Singh	$37	Hold Maintained	18 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 86 articles about HIMS published over the past 30 days

Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims

The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding they correct “false or misleading claims” about some of their popular weight-loss products after President Donald Trump signed an order designed to clamp down on drug advertising.

Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims

FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs

The Food and Drug Administration sent warning letters to dozens of drug companies this month, including popular telehealth firm Hims & Hers, demanding they correct “false or misleading claims” about some of their products, targeting the companies just days after President Donald Trump signed an order designed to clamp down on direct-to-consumer drug advertising.

FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs

Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims

Hims & Hers Health Inc. (NYSE: HIMS) saw its stock fall 6% on Tuesday following the release of a warning letter from the US Food and Drug Administration (FDA) concerning marketing claims related to its compounded semaglutide products.

Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims & Hers Health Inc. HIMS stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept.

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs

The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Wegovy.

US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs

Investors Business Daily

FDA Slams Hims & Hers With A Warning Letter. Investors Slam Hims Stock.

Hims stock toppled Tuesday after the FDA issued the telehealth giant a warning letter regarding its knockoff version of semaglutide.

FDA Slams Hims & Hers With A Warning Letter. Investors Slam Hims Stock.

The Motley Fool

Huge News for Hims & Hers Stock

Hims & Hers (HIMS -7.84%) is adding another specialty in an effort to build out its healthcare platform. The company has brought testosterone to the market, the first big addition since weight loss in 2023.

Huge News for Hims & Hers Stock

Zacks Investment Research

Hims & Hers Expands AI and Technology Focus to Advance Digital Care

HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.

Hims & Hers Expands AI and Technology Focus to Advance Digital Care

Zacks Investment Research

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $54.03, signifying a -2.65% move from its prior day's close.

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why

Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties

PHILADELPHIA , Sept. 15, 2025 /PRNewswire/ -- Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its partnership with Hims & Hers.

Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties

See News Rankings

Charts implemented using Lightweight Charts™